

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement



INSIDE INFORMATION ANNOUNCEMENT RESTRUCTURING OF SUZHOU FIRST PHARMA

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the “**SFO**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that in relation to certain lawsuits (the “**Lawsuits**”) filed by a PRC bank (the “**Creditor**”) against certain subsidiaries of the Company including, Suzhou First Pharmaceutical Co., Ltd. (蘇州第一製藥有限公司) (“**Suzhou First Pharma**”), on 27 April 2023, the People’s Court of Suzhou Industrial Park* (蘇州工業園區人民法院) (the “**Court**”) accepted the case of a restructuring (the “**Restructuring**”) of Suzhou First Pharma to be administered by an administrator (the “**Administrator**”) appointed by the Court.

The Lawsuits primarily concern the following claims. On 29 August 2022, the Creditor filed a lawsuit against Suzhou First Pharma for its non-compliance with the terms and conditions of a loan agreement entered into by Creditor (as lender) and Suzhou First Pharma (as borrower), which is guaranteed by certain other members of the Group pursuant to certain guarantee agreement, the breach of which is also being claimed for by the Creditor. According to the statement of claim, the Creditor was pursuing claims against Suzhou First Pharma for repayment of all outstanding loan principal and interest, in the sum of approximately RMB160,000,000, and repayment of the principal and interest of the outstanding loan guaranteed by Suzhou First Pharma in favour of certain other members of the Group, in the sum of approximately RMB220,000,000, together with the default interest arising from the aforesaid outstanding loans.

The Court has issued an announcement (the “**Court Announcement**”) regarding the Restructuring. Pursuant to the Court Announcement, creditors of Suzhou First Pharma should report their respective creditor’s right to the Administrator no later than 7 June 2023, and debtors of Suzhou First Pharma and persons who are in possession of assets of Suzhou First Pharma shall settle their outstanding debt and return the relevant assets (as applicable). The Court will separately announce the date of the first creditors’ meeting and the manner in which it will be convened.

Since the Lawsuits were brought, the Company has been in active discussions with the Creditor, including the Restructuring as one of the ways to settle the Lawsuits. Pursuant to the Restructuring, it is expected that the Administrator will solicit investors for the sale of Suzhou First Pharma, the proceeds from which will be utilized to settle the liabilities of the Group under the Lawsuits. If the Restructuring can be implemented on reasonable terms, the Directors believe it will allow the Company to improve its financial conditions by settling a substantial amount of its outstanding debt. Based on information currently available to the Company, certain potential purchasers have expressed interest in Suzhou First Pharma. If materialized, further announcements regarding the sale of Suzhou First Pharma as contemplated under the Restructuring will be made in this regarding in accordance with the Listing Rules as and when appropriate.

Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 2 May 2023

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Chin Yu; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao, and Mr. Ng Ming Kwan.

* *For identification purposes only*